Company / Cash & Equivalents
Definitive Healthcare Corp. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$163.6M
FY2025
5-year range
$105.4M / $387.5M
FY2021-FY2025
Trend
+55.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $164M.
Based on SEC 10-K filings.
$164M in FY2025 with a 3-year CAGR of -25.0%.
Improved from $131M to $164M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -25.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -25.0%, indicating a declining trend.
- In FY2025, cash & equivalents increased 55.3% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $163.6M | +55.3% |
| FY2024 | $105.4M | -19.5% |
| FY2023 | $131.0M | -66.2% |
| FY2022 | $387.5M | +0.0% |
| FY2021 | $387.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026